Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2013-08-19
Target enrollment:
Participant gender:
Summary
The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two
dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial
hypertension (PAH) <12 years of age.